Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 17/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13317270 | 0.92 | HTT (0.61) | HTTNR3C1NPC1RAB9ATDP1 | |
| SCHEMBL3626841 | 0.82 | NR1H3 (0.61) | NR1H3RAB9A | |
| SCHEMBL3625560 | 0.81 | NR1H3 (0.49) | NR3C1NR1H3RAB9ATDP1 | |
| SCHEMBL3626671 | 0.81 | NR1H3 (0.53) | NR1H3 | |
| SCHEMBL14537965 | 0.80 | RORC (0.51) | HTTNR3C1NR1H3NPC1RAB9A | |
| SCHEMBL3621272 | 0.80 | NR1H3 (0.58) | NR1H3RAB9ATDP1 | |
| SCHEMBL3627809 | 0.80 | NR1H3 (0.53) | NR1H3 | |
| SCHEMBL11607914 | 0.79 | NOTUM (0.64) | NR1H3 | |
| SCHEMBL3615177 | 0.79 | TSHR (0.61) | NR1H3NPC1RAB9A | |
| SCHEMBL3615173 | 0.78 | ALDH1A1 (0.60) | NR1H3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951676-B1 | N-ACYL BENZAZEPINE DERIVATIVES AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-07-17 | — | — | EP | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1951676-A2 | LXR MODULATORS | Brystol-Myers Squibb Company (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007050425-A2 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050425-A2 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093470-A1 | LXR modulators | NR1H2, NR1H3, RXRB | HTT 4381/4885NR3C1 122/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.